Remove 2003 Remove Pharma Companies Remove Research Remove Trials
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

Here, DDW’s Megan Thomas highlights the research taking place and where this is happening. This environment of research excellence, in turn, fosters R&D, innovation, spin-offs, start-ups, networking, collaboration and entrepreneurship, which sets a sturdy foundation that attracts funding, and creates an appealing work culture.

Drugs 189
article thumbnail

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects

The Pharma Data

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. The Ampligen EAP protocol is authorized to enroll up to 100 active trial participants, 20 of whom may be Long Haulers. development pipeline for ME/CFS. All study subjects will receive the same Ampligen treatments. AIM ImmunoTech Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Decentralised identities: Blockchain based informed consent

Drug Discovery World

Industry experts explain how blockchain can fundamentally enhance clinical trials. Obtaining consent from patients or healthy volunteers is a fundamental requirement for enrolling participants on to clinical trials. Along the study, patients are usually reconsented multiple times following a change in the trial protocol, eg.

article thumbnail

Decentralised identities: Blockchain based informed consent

Drug Discovery World

Industry experts explain how blockchain can fundamentally enhance clinical trials. Obtaining consent from patients or healthy volunteers is a fundamental requirement for enrolling participants on to clinical trials. Along the study, patients are usually reconsented multiple times following a change in the trial protocol, eg.